Trial Profile

An Open-label Phase II Pilot Study of Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir/ritonavir (Primary) ; Nevirapine
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms MONOGEST

Most Recent Events

30 May 2023 Results (n=89) assessing the proportion maintaining a viral load (VL) of <50 copies/mL up to delivery on darunavir/ritonavir monotherapy, without requiring treatment intensification published in the Journal of Antimicrobial Chemotherapy
05 Aug 2021 Status changed from active, no longer recruiting to completed.
27 Jul 2020 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com